CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
高度侵袭性 B 细胞淋巴瘤中的 CAR-T 细胞治疗：新兴生物学与临床见解
英文原题：CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights.
查看英文原题
CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
最近，在识别超越传统免疫化疗策略的新型疗法方面取得了显著进展，这些疗法对B细胞淋巴瘤具有疗效。其中一种方法涉及使用自体来源的嵌合抗原受体（CAR）细胞靶向B细胞上的CD19抗原。正如近期监管批准所证明的，该策略对复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）患者高度有效。近期报道表明，这也是治疗高级别B细胞淋巴瘤的有效策略。这些实体的生物学基础及其彼此之间以及与DLBCL如何重叠，仍是深入研究的领域。因此，随着对CAR-T 细胞方法经验的不断积累，思考定义这些高度侵袭性亚群的肿瘤细胞特异性和微环境因素如何影响对该方法的易感性，是令人感兴趣的。
展开英文摘要原文
Recently, significant progress has been made in identifying novel therapies, beyond conventional immunochemotherapy strategies, with efficacy in B-cell lymphomas. One such approach involves targeting the CD19 antigen on B cells with autologous-derived chimeric antigen receptor (CAR) cells.
This strategy is highly effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as evidenced by recent regulatory approvals. Recent reports suggest that this is an effective strategy for high-grade B-cell lymphoma. The biological underpinnings of these entities and how they overlap with each other and DLBCL continue to be areas of intense investigation.
Therefore, as more experience with CAR T-cell approaches is examined, it is interesting to consider how both tumor cell-specific and microenvironmental factors that define these highly aggressive subsets influence susceptibility to this approach.
论文信息
- 作者
- Ali A、Goy A、Dunleavy K
- 第一作者单位
- Stem Cell Transplant and Cellular Immunotherapy Program, Georgetown University, Washington, DC.
- 通讯作者单位
- Division of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
- 期刊
- Blood2022 Sep 29
- 原文标识
- PubMed 35560330 · DOI 10.1182/blood.2022016226